Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy

Next Previous
Trial Profile

A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine (Primary) ; Celecoxib (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Kitov Pharmaceuticals; Purple Biotech

    • Most Recent Events

    • 31 May 2018 U.S. Food and Drug Administration (FDA) has approved Consensi™ (amlodipine and celecoxib) oral tablets for treatment of osteoarthritis pain and hypertension, according to a Kitov Pharmaceuticals media release.
    • 02 Oct 2017 According to a Kitov Pharmaceuticals media release, U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for KIT-302, the FDA under the Prescription Drug User Fee Act (PDUFA), has set a target date of May 31, 2018 to complete its review.
    • 31 Jul 2017 According to a Kitov Pharmaceuticals media release, company has submitted a NDA to the U.S. FDA for KIT-302 and are on track to meet anticipated Prescription Drug User Fee Act (PDUFA) dates with respect to FDA filing the NDA in the third quarter of 2017, and rendering a decision on approval for marketing of KIT-302 during the second quarter of 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top